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Passive immunotherapy has mainly been used as a therapy against cancer and inflammatory conditions. Recent studies have
shown that monoclonal antibody-(mAb-) based passive immunotherapy is a promising approach to combat virus infection.
Specific mouse mAbs can be routinely generated in large amounts with the use of hybridoma technology but these cannot be
used for therapy in human beings due to their immunogenicity. Therefore, the development of chimeric and humanized mAbs is
important for therapeutic purpose. This is facilitated by a variety of molecular techniques like recombinant DNA technology and
the better understanding of the structure and function of antibody.The human-mouse chimeric forms allow detailed analysis of the
mechanism of inhibition and the potential for therapeutic applications. Here, a step-by-step description of the conversion process
will be described. The commercial availability of the reagents required in each step means that this experimentation can be easily
set up in research laboratories.
1. Introduction
Emil von Behring (1854–1917) won the first Nobel Prize in
medicine for demonstrating that humoral immunity could
be transferred from immunized animals to humans. Using
heterologous sera in humans had its own limitations because
of immunological reactions to serum proteins, for example,
hypersensitivity. With the help of techniques for better
purification of antibodies and monoclonal antibody (mAb)
engineering, we now have overcome many of these compli-
cations and have attained improved specificity. Till recently,
the main focus of the use of the recombinant mAb and
passive immunotherapy had been for treatment of cancers or
inflammatory conditions [1, 2].
MAb-based immunotherapy is becoming important in
infectious diseases because of widespread resistance to drugs
among pathogens, immunocompromised hosts, and the
emergence of new pathogens. For controlling pathogens
such as acute cytopathic viruses that can cause fatal damage
in infected tissues, the best way is to prevent the disease.
As vaccination is not always available or suitable, passive
immunotherapy could be used to provide protection in
the periods of high-exposure risk [3]. As immunotherapy
is a promising approach to combat virus infection, much
research efforts have been devoted to the generation and
characterisation of virus-neutralizing mAbs [4–6]. In many
laboratories, hybridoma clones are derived from mouse or
rat B-lymphocytes by fusion with myeloma cell line (e.g.,
SP2/0, NS0, NS1, Ag8, or P3U1) [7]. One major limitation
of using these hybridoma-derived mAbs is that human-anti-
mouse or human-anti-rat antibody response can occur as a
result of immunogenicity of these mouse or rat antibodies
[4]. Therefore, it is important to humanize these antibodies
for human therapeutic purposes without impacting their
binding affinity towards antigen targets. For example, in virus
research, after a mouse mAb is selected for its potent virus
neutralizing activity, it will be useful to convert it into human-
mouse chimeric form. If the human-mouse chimeric form
has similar neutralizing activity; this will be a reason for
further development for therapeutic application. Hence, the
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technique for converting mouse mAb into human-mouse
chimeric form is an emerging research tool.
Chimeric antibody has been successfully produced and
tested for specific binding activity in many previous stud-
ies [8–12]. For example, chimeric anti-human DR5 MAb
(cmDRA6) can bind to DR5 antigen as demonstrated by both
ELISA and Western blot [10]. In addition, a human-mouse
chimeric antibody generated from mAb against hepatitis
E virus (HEV) capsid proteins E2 still maintains binding
activity similar to the original mAb as shown by ELISA
and Western blot [11]. Since chimeric antibody is expected
to be less immunogenic in human, it could be suitable for
antibody therapy of viral infections. Indeed, it has been
demonstrated that patient, who received chimeric antibody
17-1A, did not show any toxic or allergic reactions and the
chimeric antibody appears significantly less immunogenic
than its parental murine antibody [13]. The construction of
human-mouse chimeric antibody basically involves cloning
and ligating of the variable region genes of mouse mAbs
into expression vectors, which have heavy- and light-chain
immunoglobulin constant regions. A simple methodology
for this conversion will be described here in a step-by-step
manner.
2. Results and Discussion
The first step is to amplify heavy- and light-chain immu-




) using the poly-
merase chain reaction (PCR). To obtain first-strand cDNA
for PCR reaction, messenger RNA (mRNA) needs to be
extracted from hybridoma cells before reverse transcription.





mainly depends on the selection of primer set and
optimised conditions of PCR reaction. Different primer sets
have been developed for amplifying the variable domains [14–
17]. Mouse Ig-Primer set is also commercially available. For
example, the one fromNovagen has been successfully applied
in many previous studies (e.g., [18–21]).
In order to determine the sequence of DNA products
from PCR, blunt end ligation with a DNA topoisomerase
provides an efficient way to clone the DNA into a vector [22].
While the use of polymerase with proofreading activity sig-
nificantly reduces the chance of mutations being introduced
in the PCR amplification step, the sequence alignment of
multiple clones will also easily reveal amismatch that is found
in a rare clone. In most of the clones, an identical sequence
should be obtained.However, if two ormore sets of sequences
are obtained, then, it is very likely that the hybridoma cells
used for mRNA extraction are heterogeneous, implicating
that hybridoma cells need to be further subcloned.





obtained, they can be subcloned into vectors containing the
constant region of the human heavy and light chain, respec-
tively (Figure 1). These vectors are designed for mammalian
expression and can be home-made or commercially available.
An example of the latter is the pair of pFUSEss-CHIg-hG1
and pFUSE2ss-CLIg-hk vectors from InvivoGen. Expression
of the human-mouse chimeric antibody is achieved by
transfecting the vectors into a transfectable mammalian cell
line like the Human Embryonic Kidney 293 cells (HEK
293). The secreted antibody can then be purified from the
culture supernatant and tested to determine if it still retains
the antigen-binding capacity after chimerization. A direct
comparison with the mouse monoclonal antibody produced
by the hybridoma will reveal if there is any incompatibility
between the mouse variable and human constant regions in
the mouse-human chimeric antibody.
The previousmethodology is summarized in Figure 1 and
has been used to convert the mouse mAb 1A9 to its chimeric
human-mouse form. mAb 1A9 is an antibody generated in
mice against the severe acute respiratory syndrome coron-
avirus (SARS-CoV) spike protein [23]. As shown in Figure 2,
both themouse 1A9 and chimeric 1A9 are able to bind to spike
protein in HEK 293-FT cell lysates that were transfected with
plasmid containing the full-length spike gene, pXJ3󸀠-S.
3. Materials and Methods





(i) Count and collect up to 5 × 106 hybridoma cells by
centrifugation (800 g for 5 minutes). Wash cells twice
with PBS and remove the supernatant completely.
Store pelleted cells at −20∘C if not used immediately.
(ii) Extract RNA from hybridoma cells using RNeasy
Mini Kit (QIAGEN). Suspend the cells in 350𝜇L lysis
buffer by vortexing and pass through QIAshredder
(QIAGEN) spin column for RNA extraction.
(iii) Produce the first-strand cDNA from the RNA using
SuperScript III First-Strand Synthesis kit (Invitro-
gen). Use 1𝜇L Novagen mouse 3󸀠 primer (Mouse






regions using Expand High
Fidelity PCR System (Roche) (Note 2). Add Novagen
5󸀠 A-B leader primers to final concentration of
10 pmol𝜇L−1 and C-G leader primers to 5 pmol𝜇L−1.
Optionally, add Novagen 3󸀠 primer to reach final
concentration of 5 pmol𝜇L−1.
(v) Run DNA gel electrophoresis on a 2% agarose gel
for PCR products. Extract the DNA bands at around
500 bp (Note 3), as determined by GeneRuler 100 bp
DNALadder (Thermo Scientific), usingQIAEX IIGel
Extraction Kit (QIAGEN). Elute DNA in nuclease-
free water.




into Vector for Sequencing





gel extraction into pCR 2.1 vector fromTOPO cloning
kit (Invitrogen). Transform ligated products into
competent TOP10 cells by heat shock method. Add
transformed bacteria onto LB agar plates, which
contain 100𝜇gmL−1 ampicillin (Sigma) and 40𝜇L
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∙ aligning sequences from 10 different clones to find the most common ones
∙ checking for no early stop codon within sequence
∙ performing Blastp search for sequence against nonredundant database (NCBI)
∙
Digested pFUSEss-CHIg-hG1 Digested pFUSE2ss-CLIg-hk
pFUSE2ss-CLIg-hk + VL
Digest with PCR-amplified VH and VL using FastDigest
restriction enzymes
Purify VH and VL by DNA Gel electrophoresis and QIAEX II
Gel Extraction kit
pFUSEss-CHIg-hG1 and pFUSE2ss-CLIg-hk plasmids
Sequence the recombinant plasmid using BigDye Terminator v3.1
Clone VH into pFUSEss-CHIg-hG1 andVL into pFUSE2ss-CLIg-hk using T4 ligase
Transform plasmid into DH5-𝛼 bacteria to obtain desirable amount of plasmid for transfection
Co-transfect both plasmids into HEK 293-FT cells
Purify antibody from cell culture supernatant using HiTrap Protein G HP column
Extract RNA using RNeasy Mini kit
using Expand High Fidelity PCR System
Produce the first-strand cDNA using SuperScript III First-Strand Synthesis kit
Ligate into pCR 2.1 vector using TOPO cloning kit
Plasmid pCR 2.1 ligated with potential
matching 5󳰀 and 3󳰀 ends of sequence to Novagen primer sequences
pCR 2.1+ verified VH and VL
pFUSEss-CHIg-hG1+ VH
Extract plasmid using AxyPrep Plasmid Miniprep kit
Figure 1: Basic molecular procedure for converting mouse mAbs to human-mouse chimeric forms.
X-gal solution (Thermo Scientific). Incubate plates
overnight at 37∘C.
(ii) Grow bacteria from at least 10 white or light blue col-
onies in LB broth containing 100 𝜇gmL−1 ampicillin
for up to 16 hours at 37∘C.
(iii) Collect up to 4mL bacteria for plasmid extraction
using AxyPrep Plasmid Miniprep Kit (Axygen Bio-
sciences). Keep bacteria in LB broth at 4∘C for short-
term storage (up to 4 weeks).
(iv) Cut recombinant plasmid (5–10 𝜇L) by FastDigest
restriction enzyme EcoRI (Thermo Scientific) and
run the DNA gel electrophoresis to confirm the
presence of DNA insert.
(v) Sequence the recombinant plasmid using BigDye
Terminator v3.1 (Applied Biosystems) with M13 for-
ward primer (5󸀠-GTAAAACGACGGCCAG-3󸀠) or
M13 reverse primer (5󸀠-CAGGAAACAGCTATGAC-
3󸀠).
(vi) Verify correct sequence by (1) aligning sequences
from 10 different clones to find the most common
ones; (2) matching 5󸀠 and 3󸀠 ends of sequence to
Novagen primer sequences; (3) checking for no early
stop codon within sequence; (4) performing Blastp






Figure 2:Western blot analysis for the detection of SARS-CoV spike
(S) protein (210 kDa). HEK 293-FT cells were transfected with no
plasmid (mock) or with plasmid expressing full-length S, pXJ3󸀠-S.
Cell lysates were separated in a 7.5% SDS-PAGE gel and detected
using mouse mAb 1A9 and human-mouse chimeric mAb 1A9 via
Western blot analysis as previously described [23].Molecular weight
markers (in kilodaltons) are indicated on the left.







(i) Transform pFUSEss-CHIg-hG1 and pFUSE2ss-CLIg-
hk plasmids (InvivoGen) separately into E. coli
DH5-𝛼 competent cells (Invitrogen) to obtain desir-
able amount of plasmid for subsequent digestion
and ligation steps. Pick up one transformed colony
from overnight-incubated plate and grow it in LB
broth with appropriate antibiotic (25𝜇gmL−1 zeocin
(InvivoGen) or 50𝜇gmL−1 blasticidin S HCl (Invivo-
Gen) up to 16 hours at 37∘C. Collect up to 100mL bac-
teria culture for plasmid extraction usingMidiprep kit
(QIAGEN).





SignalP/). Amplify the variable region without the
signal peptide domain using Expand High Fidelity
PCR System. Forward and reverse primers have 15–




plus 6 bp at 5󸀠 end as restriction sites (e.g., EcoRI
and NheI for 𝑉
𝐻
, EcoRI and BsiWI for 𝑉
𝐿
, Note 5)
and 2–4 bp before restriction sites to ensure efficient
digestion by FastDigest restriction enzymes (Thermo





is ligated into pFUSE vectors.
(iii) Digest pFUSEss-CHIg-hG1 and PCR-amplified 𝑉
𝐻
separately using the same FastDigest restriction
enzymes (e.g., EcoRI and NheI) and pFUSE2ss-CLIg-
hk plasmids and PCR-amplified 𝑉
𝐿
separately using
the same FastDigest restriction enzymes (e.g., EcoRI
and BsiWI).
(iv) Run DNA Gel electrophoresis on 1% agarose gel to
purify the digested plasmids or PCR products and
extract the DNA by using QIAEX II Gel Extraction
Kit. Elute DNA in nuclease-free water.
(v) Clone 𝑉
𝐻
into pFUSEss-CHIg-hG1 and 𝑉
𝐿
into
pFUSE2ss-CLIg-hk using T4 ligase enzyme (Thermo
Scientific).Themolar ratio ofDNA insert to vector for
ligation reaction is 3 : 1 (Note 6).
(vi) Transform the plasmid after ligation step into DH5-
𝛼 competent cells by heat shock method. Grow
pFUSEss-CHIg-hG1 with 𝑉
𝐻
on LB agar plates con-
taining 25𝜇gmL−1 zeocin and pFUSE2ss-CLIg-hk
with 𝑉
𝐿
on LB agar plates containing 50 𝜇gmL−1
blasticidin S HCl overnight at 37∘C. Pick up several
transformed colonies from plate and grow them in LB
broth with appropriate antibiotic (25𝜇gmL−1 zeocin
or 50 𝜇gmL−1 blasticidin S HCl).
(vii) Collect up to 4mL bacteria for plasmid extraction
using AxyPrep Plasmid Miniprep Kit. Keep bacteria
in LB broth at 4∘C for short-term storage (2–4 weeks).
(viii) Cut recombinant plasmid (5–10 𝜇L) by FastDigest
restriction enzymes and run the DNA gel elec-
trophoresis to confirm the presence of DNA insert.
(ix) Optional step: sequence theDNA insert in the recom-
binant plasmid using BigDye Terminator v3.1.
(x) Grow bacteria with correct recombinant plasmid
in LB broth with appropriate antibiotic (25𝜇gmL−1
zeocin or 50𝜇gmL−1 blasticidin SHCl) up to 16 hours
at 37∘C. Collect up to 100mL bacteria culture for
plasmid extraction using Midiprep kit.
3.4. Antibody Expression and Purification
(i) Seed 1.5million ofHuman Embryonic Kidney 293-FT
cells (HEK 293-FT) (Invitrogen) in 6 cm dish (Nunc)
with 3mL transfection media (Dulbecco’s Modified
Eagle’s Medium (DMEM) (Invitrogen) and 10% fetal




(ii) Add 2 𝜇g of each recombinant plasmid (pFUSEss-
CHIg-hG1 with 𝑉
𝐻
and pFUSE2ss-CLIg-hk with 𝑉
𝐿
)
and 12 𝜇L Lipofectamine 2000 (Invitrogen) to sepa-
rate tubes containing 100 𝜇L Opti-Mem (Invitrogen).
Vortex briefly and incubate at room temperature (RT)
for 5 minutes.
(iii) Spin briefly and mix Opti-Mem with plasmid and
Lipofectamine together into the same tube. Incubate
for 20 minutes at RT.
(iv) Aspirate cell culture media and gently add 1.5mL
of transfection media with mixture of Lipofectamine
and plasmid (Note 8).
(v) Swirl dish gently to mix and incubate for 4–6 hours at
37∘C and 5% CO
2
.
(vi) Gently aspirate media from the dish. Add 3mL fresh
transfectionmedia and incubate at 37∘C and 5%CO
2
.
(vii) Collect the cell culture supernatant three times after
every 24 hours with replenishment of fresh transfec-
tionmedia each time. Keep cell culture supernatant at
4∘C if not used immediately.
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(viii) Purify antibody from the cell culture supernatant
usingHiTrap Protein GHP 1mL column (GEHealth-
care) (Note 9).
(ix) Run the Bradford protein assay (Bio-Rad) with stan-
dard BSA to determine protein concentration in each
fraction.
(x) Run 3–5 eluted fractions with the highest protein
concentration on 12% SDS-PAGE and stain gel with
coomassie blue dye to visualise Ig heavy and light




3󸀠-1 for heavy chain IgM,MuIgG𝑉
𝐻
3󸀠-
2 for heavy chain IgG, MuIg𝜅𝑉
𝐿
3󸀠-1 for light chain
kappa, and MuIg𝜆𝑉
𝐿
3󸀠-1 for light chain lambda
during first-strand cDNA synthesis. If using Oligo
(dT) primer to produce the first-strand cDNA, the
Novagen 3󸀠 primer must be added in PCR reaction.
(2) Decrease the annealing temperate by steps of two
degrees if no PCR products are found. Increase the
annealing temperature by steps of two degrees ifmany
non-specific PCR products are found.
(3) Multiple bands may be present on DNA gel per reac-
tion but purify DNA from band of expected size only
(approximately 500 bp). Depending on hybridoma
source, two PCR products for 𝑉
𝐿
region may be
obtained since one is from myeloma cells [24].







(5) Restriction sites introduced to forward and reverse
primers for amplifying 𝑉
𝐻
are chosen based on
restriction sites of pFUSEss-CHIg-hG1 in the 5󸀠 to
3󸀠 direction, including EcoRI, EcoRV, XhoI, and
NheI. Restriction sites introduced to forward and
reverse primers for amplifying 𝑉
𝐿
are chosen based
on restriction sites of pFUSE2ss-CLIg-hk in the 5󸀠
to 3󸀠 direction, including EcoRI, AgeI, BstEII, NcoI,
and BsiWI. Avoid choosing the restriction site if it is









after digestion can be ligated
into the vector.
(6) Other molar ratios of insert DNA to vector, such as
5 : 1 and 1 : 1, can also be performed at the same time.
(7) After overnight growth, HEK 293-FT cells should be
around 80–90% confluent for optimal transfection.
(8) Since the HEK 293-FT cells can be easily dislodged,
themedia should be gently aspirated and added to the
same edge side of the dish.
(9) The following protocol can be alternatively used to
purify antibody from cell culture supernatant using
HiTrap Protein G HP column:
(i) attach HiTrap Protein G HP 1mL column to
a peristaltic pump and equilibrate by passing
through 10–20mL PBS at flow rate of less than
2mL per minute,
(ii) filter the culture supernatant through 0.45 𝜇m
filter to remove any cell debris and dilute the
filtrate with one volume of PBS,
(iii) pass the diluted filtrate and then 10–20mL PBS
through the HiTrap column at flow rate of 1mL
per min,
(iv) elute antibody using elution buffer 0.05M
Glycine-HCl, pH 2.7,
(v) collect and check pH of each 0.5mL fraction,
(vi) add 2.5 𝜇L of 5M NaOH for fraction with pH at
around 2.7 to return pH to 7-8.
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